To address the protein expression of COL3A1 in colon cancers, we performed an IHC analysis of COL3A1 expression using a commercially available TMA containing 90 cases of colorectal adenocarcinoma, which 46 cases were completed and 44 were censored (Supplementary Table 1). This evidence concerns the gene COL3A1 and malignant colon neoplasm.